Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Alnylam Pharmaceuticals Shares Soared

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY  ) , a biopharmaceutical company developing treatments based on RNA interference, vaulted 19% higher after the company announced positive top-line data for ALN-TTRsc.

So what: In early-stage trials, initial data showed that a subcutaneous treatment targeting TTR-mediated amyloidosis achieved statistical significant results by knocking down serum TTR levels in patients by greater than 80%. The true excitement comes from the quickness of subcutaneous injection as compared to intravenous injection, and the fact that most patients are more willing to get medication subcutaneously than through an IV. Alnylam anticipates beginning a phase 2 trial for ALN-TTRsc later this year and, if all goes well, initiate a phase 3 trial sometime next year.

Now what: Both of Alnylam's TTR-mediated amyloidosis drugs have shown considerable promise in trials -- ALN-TTR02, an intravenous application to treat familial amyloidotic polyneuropathy (FAP), and ALN-TTRsc for familial amyloidotic cardiomyopathy (FAC). There are four times as many cases of FAC worldwide, so it's not hard to understand why investors are excited about this early stage news. As for me, I still remain skeptical of Alnylam's valuation at these levels. My suggestion would be to watch Alnylam closely, but do it from a safe distance!

It's no secret that biotech stocks like Alnylam Pharmaceuticals have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2532649, ~/Articles/ArticleHandler.aspx, 9/26/2016 10:09:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 53 minutes ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
ALNY $76.00 Up +0.43 +0.57%
Alnylam Pharmaceut… CAPS Rating: ****